Oncimmune Regulatory News (ONC)

15 March 2021

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Issue of Equity and Total Voting Rights

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, today announces the allotment of equity in connection with the final tranche of consideration for the acquisition of Protagen Diagnostics AG (now Oncimmune Germany GmbH).

On 19 March 2019, the Company announced the acquisition of Protagen Diagnostics AG, a leader in personalised immune-profiling (the "Acquisition"). The consideration for the Acquisition, of up to £4.11m, was to be satisfied by the allotment of up to 2,635,910 ordinary shares of 1p each in the Company at a price of 156p per share ("Consideration Shares") as follows:

· 1,623,890 Consideration Shares on completion of the transaction ("Completion"). Such shares were allotted and then admitted to trading on AIM in March 2019;

· 374,744 Consideration Shares if Protagen signed revenue-generating contracts to the aggregate value of at least EUR 0.5 million in the period ending 28 February 2020 ("Tranche 1 Deferred Shares"). This target had not been met by 28 February 2020 and therefore the Tranche 1 Deferred Shares were not allotted;

· 249,830 Consideration Shares if certain named key employees of Protagen remain employed by the enlarged group 12 months after Completion ("Tranche 2 Deferred Shares"). This condition had been satisfied and therefore the Tranche 2 Deferred Shares were allotted and then admitted to trading on AIM in March 2020; and

· 387,447 Consideration Shares on the date falling 24 months after the Completion date ("Tranche 3 Deferred Shares").

The Tranche 3 Deferred Shares have now been allotted by the Company conditional on Admission. Accordingly, application has been made for 387,447 Consideration Shares to be admitted to trading on AIM and dealings in those Consideration Shares are expected to commence on 19 March 2021. The new Consideration Shares will, when issued, rank pari passu with the existing ordinary shares of the Company.

Following admission of the Tranche 3 Deferred Shares, the total number of ordinary shares and voting rights in the Company will be 64,097,540. The Company does not hold any shares in treasury.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information:

Oncimmune Holdings plc

Adam Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

contact@oncimmune.co.uk

Zeus Capital Limited (Nominated Adviser)

Andrew Jones, Daniel Harris, Victoria Ayton

+44 (0)20 3829 5000

N+1 Singer (Joint Broker)

Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer

+44 (0)20 7496 3000

WG Partners (Joint Broker)

David Wilson, Chris Lee

+44 (0)203 705 9321

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

Oncimmune@fticonsulting.com

+44 (0)20 3727 1000